微生物群
癌症
免疫系统
癌症免疫疗法
疾病
免疫疗法
医学
抗生素
免疫检查点
精密医学
人体微生物群
生物
计算生物学
生物信息学
免疫学
内科学
微生物学
遗传学
作者
Laurence Zitvogel,Yuting Ma,Didier Raoult,Guido Kroemer,Thomas F. Gajewski
出处
期刊:Science
[American Association for the Advancement of Science (AAAS)]
日期:2018-03-23
卷期号:359 (6382): 1366-1370
被引量:531
标识
DOI:10.1126/science.aar6918
摘要
The fine line between human health and disease can be driven by the interplay between host and microbial factors. This “metagenome” regulates cancer initiation, progression, and response to therapies. Besides the capacity of distinct microbial species to modulate the pharmacodynamics of chemotherapeutic drugs, symbiosis between epithelial barriers and their microbial ecosystems has a major impact on the local and distant immune system, markedly influencing clinical outcome in cancer patients. Efficacy of cancer immunotherapy with immune checkpoint antibodies can be diminished with administration of antibiotics, and superior efficacy is observed with the presence of specific gut microbes. Future strategies of precision medicine will likely rely on novel diagnostic and therapeutic tools with which to identify and correct defects in the microbiome that compromise therapeutic efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI